COMP <GO>
CRVS vs PHAR // EV/EBITDA & P/E VALUATION
Corvus Pharmaceuticals Inc. (NASDAQ) VS. Pharming Group N.V. ADS each representing 10 (NASDAQ) • 15-METRIC TALLY: CRVS 1
— PHAR 1
■ METRIC PARITY
LAST: $10.23 (-2.76%) • MKT CAP: $860.6M
valuation
—
LAST: $12.13 (-1.06%) • MKT CAP: $856.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CRVS VS. PHAR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CRVS | PHAR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.83% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 39.6 | 70.1 | -30.46 | PHAR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $860.6M | $856.7M | $3.9M | CRVS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CRVS REV | PHAR REV | CRVS GROSS % | PHAR GROSS % | CRVS FCF | PHAR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | — | — | — | -$33.0M | — |
| FY 2024 | $0 | — | — | — | -$25.4M | — |
| FY 2023 | $0 | — | — | — | -$23.9M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CRVS // BETA —
PHAR // BETA —